磷酸二酯酶-4抑制剂治疗慢性阻塞性肺疾病最新研究进展  

Recent development in the treatment of chronic obstructive pulmonary disease with phosphodiesterase 4 inhibitors

作　　者：孙玉杰 顾丰华 SUN Yujie;GU Fenghua(State Key Laboratory of&New Drug Pharmaceutical Process,China State Institute of Pharmaceutical Industry,Shanghai 200437,China;Shanghai Technical Service Platform for Biological Material Druggability Evaluation,Shanghai 200437,China)

机构地区：[1]中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海200437 [2]上海市生物物质成药性评价技术服务平台,上海200437

出　　处：《世界临床药物》2022年第4期480-484,共5页World Clinical Drug

摘　　要：慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种具有气流阻塞特征的慢性支气管炎和(或)肺气肿疾病,患病率和死亡率逐年增加。尽管临床上治疗COPD的药物种类有很多,但COPD患者的临床需求仍未得到满足。近年来,磷酸二酯酶-4抑制剂(phosphodiesterase 4 inhibitors,PDE4I)成为研究热点,现将PDE4I最新研究进展作一综述,旨在为临床新药开发提供参考。Chronic obstructive pulmonary disease(COPD)is a chronic bronchitis and/or emphysema disease characterized by airflow obstruction,and the morbidity and mortality are increasing year by year.Although there are many kinds of drugs for the treatment of COPD,the clinical needs of patients with COPD are still unmet.In recent years,phosphodiesterase 4 inhibitor(PDE4I)has become a research hotspot.This article reviewed the latest research progress of PDE4I,in order to provide reference for the development of clinical new drugs.

关 键 词：磷酸二酯酶-4抑制剂 慢性阻塞性肺疾病 研究进展 

分 类 号：R563[医药卫生—呼吸系统] R974[医药卫生—内科学]